JP2021502400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502400A5 JP2021502400A5 JP2020526289A JP2020526289A JP2021502400A5 JP 2021502400 A5 JP2021502400 A5 JP 2021502400A5 JP 2020526289 A JP2020526289 A JP 2020526289A JP 2020526289 A JP2020526289 A JP 2020526289A JP 2021502400 A5 JP2021502400 A5 JP 2021502400A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- disease
- syndrome
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003251 Pruritus Diseases 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 206010025135 lupus erythematosus Diseases 0.000 claims 21
- 208000011580 syndromic disease Diseases 0.000 claims 20
- 201000004384 Alopecia Diseases 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 230000007803 itching Effects 0.000 claims 18
- 208000010201 Exanthema Diseases 0.000 claims 16
- 231100000360 alopecia Toxicity 0.000 claims 16
- 201000005884 exanthem Diseases 0.000 claims 16
- 206010037844 rash Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 241000519995 Stachys sylvatica Species 0.000 claims 15
- 206010016654 Fibrosis Diseases 0.000 claims 14
- 230000001363 autoimmune Effects 0.000 claims 14
- 230000004761 fibrosis Effects 0.000 claims 14
- 206010028537 myelofibrosis Diseases 0.000 claims 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- 206010047115 Vasculitis Diseases 0.000 claims 8
- 230000001154 acute effect Effects 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 210000000440 neutrophil Anatomy 0.000 claims 7
- 230000037390 scarring Effects 0.000 claims 7
- 208000017520 skin disease Diseases 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 206010040070 Septic Shock Diseases 0.000 claims 6
- 150000001345 alkine derivatives Chemical class 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 206010040047 Sepsis Diseases 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 208000024780 Urticaria Diseases 0.000 claims 5
- 230000000735 allogeneic effect Effects 0.000 claims 5
- 210000003734 kidney Anatomy 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000003476 primary myelofibrosis Diseases 0.000 claims 5
- 206010003645 Atopy Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000003176 fibrotic effect Effects 0.000 claims 4
- 210000003128 head Anatomy 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000000366 juvenile effect Effects 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 231100000241 scar Toxicity 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 210000000941 bile Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 210000004209 hair Anatomy 0.000 claims 3
- 208000024963 hair loss Diseases 0.000 claims 3
- 230000003676 hair loss Effects 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000013223 septicemia Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 2
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010013886 Dysaesthesia Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 208000037581 Persistent Infection Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 2
- 206010039509 Scab Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000001815 facial effect Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 201000003265 lymphadenitis Diseases 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 208000035824 paresthesia Diseases 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000001107 psychogenic effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 230000037387 scars Effects 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 210000004243 sweat Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000003014 Bites and Stings Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010073960 CANDLE syndrome Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000022306 Cerebral injury Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005171 Cystadenoma Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000035690 Familial cold urticaria Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016936 Folliculitis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 241000270322 Lepidosauria Species 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 101100095974 Mus musculus Smc3 gene Proteins 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000237509 Patinopecten sp. Species 0.000 claims 1
- 208000022463 Pediatric systemic lupus erythematosus Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 claims 1
- 201000003699 Punctate palmoplantar keratoderma Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 206010037884 Rash pruritic Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000010265 Sweet syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000002777 columnar cell Anatomy 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000004709 eyebrow Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 230000002631 hypothermal effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 206010023365 keratopathy Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000005015 neuronal process Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000002674 obstructive nephropathy Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004535 ovarian dysfunction Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 208000017983 photosensitivity disease Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 208000012113 pregnancy disease Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 235000020637 scallop Nutrition 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 231100000121 skin sensitizing Toxicity 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000009996 subepithelial mucinous corneal dystrophy Diseases 0.000 claims 1
- 230000009182 swimming Effects 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198813A JP7607732B2 (ja) | 2017-11-03 | 2023-11-24 | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581428P | 2017-11-03 | 2017-11-03 | |
| US62/581,428 | 2017-11-03 | ||
| US201862670448P | 2018-05-11 | 2018-05-11 | |
| US62/670,448 | 2018-05-11 | ||
| PCT/US2018/059071 WO2019090158A1 (en) | 2017-11-03 | 2018-11-02 | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198813A Division JP7607732B2 (ja) | 2017-11-03 | 2023-11-24 | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502400A JP2021502400A (ja) | 2021-01-28 |
| JP2021502400A5 true JP2021502400A5 (https=) | 2021-11-25 |
Family
ID=66328264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526289A Pending JP2021502400A (ja) | 2017-11-03 | 2018-11-02 | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 |
| JP2023198813A Active JP7607732B2 (ja) | 2017-11-03 | 2023-11-24 | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198813A Active JP7607732B2 (ja) | 2017-11-03 | 2023-11-24 | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10981906B2 (https=) |
| EP (1) | EP3710431A4 (https=) |
| JP (2) | JP2021502400A (https=) |
| KR (1) | KR102821964B1 (https=) |
| CN (2) | CN119119039A (https=) |
| AU (2) | AU2018360059B2 (https=) |
| BR (1) | BR112020008850A2 (https=) |
| CA (1) | CA3081751A1 (https=) |
| MX (1) | MX2020004946A (https=) |
| PH (1) | PH12020550499A1 (https=) |
| SG (1) | SG11202002947TA (https=) |
| WO (1) | WO2019090158A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200629A (en) | 2017-08-01 | 2024-01-06 | Theravance Biopharma R&D Ip Llc | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors |
| EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| WO2020033955A1 (en) | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2020223728A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| AU2021350089A1 (en) * | 2020-09-25 | 2023-04-13 | Aclaris Therapeutics, Inc. | Crystalline polymorph form a of a jak inhibitor and methods for its preparation |
| TW202302104A (zh) * | 2021-02-18 | 2023-01-16 | 美商阿克拉里斯醫療股份有限公司 | Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法 |
| CN117279915A (zh) * | 2021-02-18 | 2023-12-22 | 阿克拉瑞斯治疗股份有限公司 | Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法 |
| WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023151069A1 (zh) * | 2022-02-14 | 2023-08-17 | 湖南南新制药股份有限公司 | 吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途 |
| WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
| US12564326B2 (en) | 2022-10-25 | 2026-03-03 | GE Precision Healthcare LLC | Non-invasive bilirubin detection using induced photoreaction |
| WO2025038910A1 (en) * | 2023-08-16 | 2025-02-20 | Aclaris Therapeutics, Inc. | Crystalline polymorph form a of a jak inhibitor and methods for its preparation |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2141916T3 (es) | 1993-11-30 | 2000-04-01 | Searle & Co | Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion. |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006127587A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| CN101223168A (zh) * | 2005-07-14 | 2008-07-16 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| EP2123651A4 (en) | 2007-01-12 | 2011-05-04 | Astellas Pharma Inc | CONDENSED PYRIDINE COMPOUND |
| EP3070090B1 (en) * | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| US8158616B2 (en) * | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| KR20120102724A (ko) * | 2009-12-01 | 2012-09-18 | 아보트 러보러터리즈 | 신규한 트리사이클릭 화합물 |
| US9273028B2 (en) * | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| WO2012068440A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2818542A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| JP6248948B2 (ja) * | 2013-02-08 | 2017-12-20 | 日産化学工業株式会社 | ３環性ピロロピリジン化合物及びｊａｋ阻害剤 |
| MX368464B (es) | 2013-12-05 | 2019-10-02 | Pfizer | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo. |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| CR20160525A (es) | 2014-05-14 | 2016-12-20 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2017097224A1 (zh) * | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
| TW201811795A (zh) | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
| US10800775B2 (en) | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| EP3710431A4 (en) | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES |
| WO2020033955A1 (en) | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| WO2020223728A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| CA3150975A1 (en) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
-
2018
- 2018-11-02 EP EP18874287.8A patent/EP3710431A4/en active Pending
- 2018-11-02 CN CN202411261119.4A patent/CN119119039A/zh active Pending
- 2018-11-02 AU AU2018360059A patent/AU2018360059B2/en active Active
- 2018-11-02 CN CN201880082616.4A patent/CN111566095B/zh active Active
- 2018-11-02 MX MX2020004946A patent/MX2020004946A/es unknown
- 2018-11-02 JP JP2020526289A patent/JP2021502400A/ja active Pending
- 2018-11-02 US US16/179,695 patent/US10981906B2/en active Active
- 2018-11-02 BR BR112020008850-1A patent/BR112020008850A2/pt unknown
- 2018-11-02 SG SG11202002947TA patent/SG11202002947TA/en unknown
- 2018-11-02 WO PCT/US2018/059071 patent/WO2019090158A1/en not_active Ceased
- 2018-11-02 CA CA3081751A patent/CA3081751A1/en active Pending
- 2018-11-02 KR KR1020207015703A patent/KR102821964B1/ko active Active
-
2020
- 2020-04-24 PH PH12020550499A patent/PH12020550499A1/en unknown
-
2021
- 2021-03-16 US US17/203,482 patent/US11739086B2/en active Active
-
2023
- 2023-07-03 US US18/217,874 patent/US12281111B2/en active Active
- 2023-10-12 AU AU2023248127A patent/AU2023248127B2/en not_active Expired - Fee Related
- 2023-11-24 JP JP2023198813A patent/JP7607732B2/ja active Active
-
2025
- 2025-03-21 US US19/086,512 patent/US20260062410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502400A5 (https=) | ||
| CN110016025B (zh) | 一种免疫调节剂 | |
| CN109689673B (zh) | C17、c20和c21取代的神经活性类固醇及其使用方法 | |
| IL315950A (en) | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline | |
| JP2021534244A5 (https=) | ||
| CN112204024A (zh) | Erk抑制剂及其应用 | |
| CN109071509A (zh) | 作为ROR-γ的调节剂的苯并咪唑衍生物 | |
| TW201625661A (zh) | 神經活性類固醇，其組合物及其用途 | |
| CN110563700A (zh) | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 | |
| JP2024040444A (ja) | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド | |
| CN115160297B (zh) | 杂芳基化合物及其制备方法和用途 | |
| CN114456147A (zh) | 氧取代氨基碳酸酯噻吩类化合物 | |
| WO2022100625A1 (zh) | 氮取代氨基碳酸酯噻吩类化合物及其用途 | |
| TW202024093A (zh) | 作為抗病毒劑之官能化雜環 | |
| CN116462679A (zh) | 一种吡唑并嘧啶衍生物及其在医药上的应用 | |
| CN118510779A (zh) | 三环稠杂环类pde3/4双重抑制及其用途 | |
| KR20220061189A (ko) | 테트라사이클린계 피리미디논류 화합물, 그 제조방법, 그 조성물 및 사용 | |
| TW202515544A (zh) | 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物 | |
| CN117062819A (zh) | 多环化合物及其用途 | |
| CN109952298B (zh) | 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用 | |
| KR20180114057A (ko) | 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도 | |
| CN115210235A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 | |
| CN109721605A (zh) | 一种免疫细胞迁徙抑制剂 | |
| CN114341145A (zh) | 化学化合物 | |
| CN117964637A (zh) | 一种新型肽基腈类化合物及其应用 |